Short answer
Zoetis (ZTS) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.4B (up 0.5% year over year) with net income of $721M.
Q3 2025 key financials · XBRL
- Revenue
- $2.4B
- +0.5% YoY · −2.4% QoQ
- Net income
- $721M
- +5.7% YoY · +0.4% QoQ
- EPS (diluted)
- $1.63
- +7.9% YoY · +1.2% QoQ
Source: XBRL data from the Zoetis (ZTS) Q3 2025 10-Q on SEC EDGAR. USD.
Zoetis Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.40B, up 1% YoY (+$12M); nine months revenue $7.08B, up 2% YoY (+$141M) with 3% operational growth
- Operating margin U.S. 83.2% vs 80.8% YoY Q3; International 68.6% vs 68.6% flat Q3; Nine months U.S. 83.7% vs 81.5%, Intl 69.8% vs 68.1%
- Best performing: U.S. companion animal revenue +$1M Q3, +$172M nine months; Worst performing: U.S. livestock revenue down $25M Q3, $128M nine months due to MFA divestiture
- Cash and equivalents $2.08B Sept 30, 2025 vs $1.99B Dec 31, 2024; Operating cash flow $2.01B for nine months (-$37M YoY); Capital expenditures increase led investing cash use $582M vs $441M
- Near-term risks: US and global tariffs, disease outbreaks impacting livestock demand, foreign exchange headwinds, inflation; management maintains liquidity and debt covenant compliance; $4.5B share repurchase authorization remaining
Risk Factors
- New risk: Impact of dynamic and unpredictable new tariffs and trade restrictions on costs and supply chains triggered by recent foreign trade policy changes
- Most updated risk: Increased supply chain disruptions and labor/material cost volatility due to evolving tariffs and geopolitical tensions affecting third-party suppliers
- Regulatory risk: Complex international sanctions compliance with example of prior OFAC investigation and July 2023 No Action letter concluding no further penalties
- Operational risk: Potential supply shortages from sole-source third-party suppliers amid escalating trade disputes and import/export restrictions disrupting production
- Financial risk: Exposure to rising manufacturing costs and inability to pass on full cost increases to customers could materially reduce operating results and financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zoetis quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.